

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/518,813 03/03/2000		Carr Franis Joseph	102286.412	6951
7	590 06/17/2002			
Hale and Dorr L L P			EXAMINER	
60 State Street Boston, MA 02109			PONNALURI, PADMASHI	PADMASHRI
			ART UNIT	PAPER NUMBER
			1627	14
			DATE MAILED: 06/17/2002	\ I

Please find below and/or attached an Office communication concerning this application or proceeding.

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/518,813	3/3/00		

٦

P. Ponnaluri

ART UNIT PAPER NUMBER

1627 14

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2)(i.e., see the primer sequences in page 55). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. The specification has numerous sequences which do not comply with sequence rules.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

PLEASE NOTE: A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

- 1. Electronically submitted through EFS-Bio (<<u>http://www.uspto.gov/ebc/efs/downloads/documents.htm></u>>, EFS Submission User Manual ePAVE)
- 2. Mailed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

L

3. Mailed by Federal Express, United Parcel Service or other delivery service to:

U. S. Patent and Ademark Office 2011 South Clark Place Customer Window, Box Sequence Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

4. Hand Carried directly to the Customer Window at: 2011 South Clark Place Crystal Plaza Two, Lobby, Room 1B03, Box Sequence, Arlington, Virginia 22202

Any inquiry concerning this communication should be directed to P. Ponnaluri whose telephone number is (703) 305-3884. The examiner can normally be reached on Monday through Friday from 8:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat, can be reached at (703)308-2439. The fax number for this group is (703)305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703)308-0196.

P. Ponnaluri
Patent Examiner
Technology center 1600
Art Unit 1627
12 June 2002

PADMASHRI PONNALURI PRIMARY EXAMINER Application No.: 09/518,813

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. Other: all the sequences in the specification do not comply with the sequence rules (i.e., see page 55, line 24)
App	olicant Must Provide:
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Foi	questions regarding compliance to these requirements, please contact:
	r Rules Interpretation, call (703) 308-4216
	r CRF Submission Help, call (703) 308-4212
Pat	tentIn Software Program Support (SIRA) Technical Assistance703-287-0200
	To Purchase Patentin Software 703 306 2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE